BIOHIT OYJ STOCK EXCHANGE RELEASE 6 MAY 2010 AT 01:45 PM
CHANGES IN BIOHIT OYJ'S MANAGEMENT TEAM
MSc (biochem), Mr Jukka-Pekka Haapalahti, (born 1975) has been appointed VP of
liquid handling sales and marketing in Biohit Oyj as of 10th May 2010,
replacing Mikko Patrakka, who earlier held the position. Prior to joining
Biohit, Mr Haapalahti worked for Roche Diagnostics GmbH in sales and marketing
senior management positions.
MBA, Ms Tiina Hankonen (born 1967) has been appointed CFO to Biohit Oyj as of
7th June 2010. Ms Hankonen is joining Biohit from Basware Oyj, a Finnish
publicly listed company, where she has been working for 11 years, the last
three years as VP of Financial Shared Services.
Further information:
Jussi Heiniö
VP, Administration and Legal Affairs
Tel: +358-9-773 861
Email: jussi.heinio@biohit.com
Distribution:
NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com
About Biohit Oyj
Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on
the global market. Biohit's operations are based on a goal-oriented and
long-term innovation and patenting strategy.
Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of
the gastrointestinal tract.
Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions,
healthcare and industrial laboratories.
The diagnostics business comprises products and analysis systems for the early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk of colorectal
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic
stomachs.
The Biohit Group employs around 390 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA, as well as a representative office in
Singapore. Additionally, Biohit's products are sold by approximately 450
distributors in 70 countries.
Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small
cap/Healthcare since 1999.
Read more at www.biohit.com